Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study

In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU plus bevacizumab and anakinra (an IL-1β and α inhibitor) in patients with metastatic colorectal (mCRC) refractory to chemotherapy and anti-ang...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Isambert, Nicolas, Hervieu, Alice, Rébé, Cedric, Hennequin, Audrey, Borg, Christophe, Zanetta, Sylvie, Chevriaux, Angélique, Richard, Corentin, Derangère, Valentin, Limagne, Emeric, Blanc, Julie, Bertaut, Aurélie, Ghiringhelli, François
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6140586/
https://ncbi.nlm.nih.gov/pubmed/30228942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1474319
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi